Christopher Pittenger, MD, PhD | Psychiatrist.com

Original Research

N-Acetylcysteine Augmentation for Treatment-Resistant OCD

August 23, 2017

About half of OCD patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment. This randomized controlled trial examined whether N-acetylcysteine, a...

Daniel L. C. Costa, Juliana B. Diniz, Guaraci Requena, et al

Meta-Analysis

Early Onset of SSRI for OCD

May 25, 2016

Should you be concerned about your patients with OCD who aren't responding to an SSRI? Review results of 17 trials with over 3,000 patients.

Yasmin Issari, Ewgeni Jakubovski, Christine A. Bartley, et al

Original Research

Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder: A Pilot Randomized Placebo-Controlled Trial

August 26, 2015

Christopher Pittenger, Michael H. Bloch, Suzanne Wasylink, et al

Letter to the Editor

Gabapentin Abuse & Delirium Tremens Withdrawal

March 15, 2007

Read a letter to the editor on Gabapentin (Neurontin) Abuse, and Delirium Tremens (DTs) upon Withdrawal.

Christopher Pittenger, Paul H. Desan

Letter to the Editor

Beneficial Effects of the Antiglutamatergic Agent Riluzole in a Patient Diagnosed With Trichotillomania

January 15, 2007

Vladimir Coric, Ben Kelmendi, Christopher Pittenger, et al

Letter to the Editor

Initial Evidence of the Beneficial Effects of Glutamate-Modulating Agents in the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder

November 15, 2005

Christopher Pittenger, John H. Krystal, Vladimir Coric